News >

Immunotherapy Combo Strategies Are Major Research Focus in Ovarian Cancer

Gina Columbus @ginacolumbusonc
Published: Tuesday, Aug 20, 2019

Brian Orr, MD

Brian Orr, MD

Exploring checkpoint inhibitors in combination with PARP inhibitors, other immunotherapies, and chemotherapy are all novel tactics that could demonstrate improved activity versus single-agent immunotherapy, explained Brian Orr, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Oncology Briefings™: A Nurses' Guide to Managing Adverse Events Associated with PARP InhibitorsJun 30, 20201.0
Publication Bottom Border
Border Publication
x